File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology

TitleManagement of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
Authors
KeywordsMedicine & Public Health
Rheumatology
Issue Date2010
PublisherSpringer London
Citation
Clinical Rheumatology, 2010, v. 30, n. 3, p. 303-312 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/147093
ISSN
2015 Impact Factor: 2.042
2015 SCImago Journal Rankings: 0.697
ISI Accession Number ID
References

Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229 doi: 10.1186/ar2669

Xiang YJ, Dai SM (2009) Prevalence of rheumatic diseases and disability in China. Rheumatol Int 29:481–490 doi: 10.1007/s00296-008-0809-z

Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916 doi: 10.1056/NEJM200103223441207

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324 doi: 10.1002/art.1780310302

Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 doi: 10.1136/ard.2010.138461

Combe B, Landewe R, Lukas C et al (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34–45 doi: 10.1136/ard.2005.044354

Lard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446–451 doi: 10.1016/S0002-9343(01)00872-5

O’Dell JR (2004) Therapeutic strategies for Rheumatoid arthritis. N Engl J Med 350:2591–2602 doi: 10.1056/NEJMra040226

Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 54:26–37 doi: 10.1002/art.21519

St Clair EW, van der Heijde DM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443 doi: 10.1002/art.20568

Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269 doi: 10.1016/S0140-6736(04)16676-2

Poleksic L, Zdravkovic D, Jablanovic D, Watt I, Bacic G (1993) Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol 22:577–580 doi: 10.1007/BF00197138

Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757 doi: 10.1016/j.rdc.2009.10.001

Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA (1997) Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463–469 doi: 10.1136/ard.56.8.463

Masdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H (2000) Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 39:1202–1205 doi: 10.1093/rheumatology/39.11.1202

Forslind K, Ahlmén M, Eberhardt K, Hafström I, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095 doi: 10.1136/ard.2003.014233

Möttönen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P (1998) Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with “sawtooth” strategy. Ann Rheum Dis 57:533–539 doi: 10.1136/ard.57.9.533

Richi P, Balsa A, Muñoz-Fernández S et al (2002) Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis. Ann Rheum Dis 61:270–272 doi: 10.1136/ard.61.3.270

Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907–927 doi: 10.1016/j.berh.2007.05.007

Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784 doi: 10.1002/art.23721

Lillegraven S, Kvien TK (2007) Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:827–840 doi: 10.1016/j.berh.2007.05.004

van der Heijde D, Klareskog L, Boers M et al (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64:1582–1587 doi: 10.1136/ard.2004.034371

Weinblatt ME, Coblyn JS, Fox DA et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822 doi: 10.1056/NEJM198503283121303

Weinblatt ME, Kaplan H, Germain BF et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1498 doi: 10.1002/art.1780371013

Mikuls TR, O’Dell JR (2000) The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 43:464–465 doi: 10.1002/1529-0131(200002)43:2%3C464::AID-ANR30%3E3.0.CO;2-U

Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33:1449–1461 doi: 10.1002/art.1780331001

Boers M, Verhoeven AC, Markusse HM et al (1997) Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318 doi: 10.1016/S0140-6736(97)01300-7

Landewe RB, Boers M, Verhoeven AC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347–356 doi: 10.1002/art.10083

Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681 doi: 10.1016/S0140-6736(04)15640-7

Möttönen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. The Lancet 353:1568–1573 doi: 10.1016/S0140-6736(98)08513-4

Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259 doi: 10.1056/NEJM199901283400401

Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411 doi: 10.1002/art.20217

Maini RN, Breedveld FC, Kalden JR et al (2004) Sustained improvement over 2 years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065 doi: 10.1002/art.20159

Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523 doi: 10.1136/ard.2008.092932

Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829 doi: 10.1002/art.22033

Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997 doi: 10.1016/S0140-6736(08)60453-5

Jones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96 doi: 10.1136/ard.2008.105197

Kremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963 doi: 10.1002/art.23397

Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 54:2793–2806 doi: 10.1002/art.22025

Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123 doi: 10.1056/NEJMoa050524

Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44:714–720 doi: 10.1093/rheumatology/keh567

Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989 doi: 10.1136/ard.2005.043257

Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371 doi: 10.1111/j.1440-1746.2006.04559.x

Stone JH, Holbrook JT, Marriott MA et al (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:1608–1618 doi: 10.1002/art.21869

Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426 doi: 10.1136/ard.2004.033993

Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703 doi: 10.1136/ard.2004.030528

Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602 doi: 10.1161/01.CIR.0000124490.27666.B2

Chung ES, Packer M, Lo KH, Fasanmade AA (2003) Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140 doi: 10.1161/01.CIR.0000077913.60364.D2

Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biologic agents: a double-edged sword? Autoimmun Rev 9:188–193 doi: 10.1016/j.autrev.2009.10.003

Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412 doi: 10.1002/art.21386

Curtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 56:1125–1133 doi: 10.1002/art.22504

Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357 doi: 10.1007/s10165-009-0197-6

Turesson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63:952–955 doi: 10.1136/ard.2003.018101

Solomon DH, Karlson EW, RImm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307 doi: 10.1161/01.CIR.0000054612.26458.B2

Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331 doi: 10.1136/ard.2009.113696

 

DC FieldValueLanguage
dc.contributor.authorLai Shan Tamen_US
dc.contributor.authorTak Hin Chanen_US
dc.contributor.authorGavin K. W. Leeen_US
dc.contributor.authorEdmund K. M. Lien_US
dc.contributor.authorHong Kong Society of Rheumatologyen_US
dc.contributor.authorChi Chiu Moken_US
dc.date.accessioned2012-05-25T07:50:37Z-
dc.date.available2012-05-25T07:50:37Z-
dc.date.issued2010en_US
dc.identifier.citationClinical Rheumatology, 2010, v. 30, n. 3, p. 303-312en_US
dc.identifier.issn0770-3198en_US
dc.identifier.urihttp://hdl.handle.net/10722/147093-
dc.languageengen_US
dc.publisherSpringer Londonen_US
dc.relation.ispartofClinical Rheumatologyen_US
dc.rightsThe Author(s)en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectMedicine & Public Healthen_US
dc.subjectRheumatologyen_US
dc.titleManagement of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatologyen_US
dc.typeArticleen_US
dc.identifier.openurlhttp://www.springerlink.com/link-out/?id=2104&code=J88377273V37071V&MUD=MPen_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s10067-010-1596-yen_US
dc.identifier.pmid21046421-
dc.identifier.scopuseid_2-s2.0-79954569790en_US
dc.relation.referencesGabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229en_US
dc.relation.referencesdoi: 10.1186/ar2669en_US
dc.relation.referencesLau E, Symmons D, Bankhead C et al (1993) Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. J Rheumatol 20:1133–1137en_US
dc.relation.referencesXiang YJ, Dai SM (2009) Prevalence of rheumatic diseases and disability in China. Rheumatol Int 29:481–490en_US
dc.relation.referencesdoi: 10.1007/s00296-008-0809-zen_US
dc.relation.referencesChoy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916en_US
dc.relation.referencesdoi: 10.1056/NEJM200103223441207en_US
dc.relation.referencesOlech E, Freeston JE, Conaghan PG et al (2008) Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. J Rheumatol 35:580–583en_US
dc.relation.referencesArnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324en_US
dc.relation.referencesdoi: 10.1002/art.1780310302en_US
dc.relation.referencesAletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588en_US
dc.relation.referencesdoi: 10.1136/ard.2010.138461en_US
dc.relation.referencesCombe B, Landewe R, Lukas C et al (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34–45en_US
dc.relation.referencesdoi: 10.1136/ard.2005.044354en_US
dc.relation.referencesLard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446–451en_US
dc.relation.referencesdoi: 10.1016/S0002-9343(01)00872-5en_US
dc.relation.referencesO’Dell JR (2004) Therapeutic strategies for Rheumatoid arthritis. N Engl J Med 350:2591–2602en_US
dc.relation.referencesdoi: 10.1056/NEJMra040226en_US
dc.relation.referencesBreedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 54:26–37en_US
dc.relation.referencesdoi: 10.1002/art.21519en_US
dc.relation.referencesSt Clair EW, van der Heijde DM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443en_US
dc.relation.referencesdoi: 10.1002/art.20568en_US
dc.relation.referencesGrigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269en_US
dc.relation.referencesdoi: 10.1016/S0140-6736(04)16676-2en_US
dc.relation.referencesNishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808en_US
dc.relation.referencesWakefield RJ, Gibbon WW, Conaghan PG et al (2000) The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43:2762–2770en_US
dc.relation.referencesPoleksic L, Zdravkovic D, Jablanovic D, Watt I, Bacic G (1993) Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol 22:577–580en_US
dc.relation.referencesdoi: 10.1007/BF00197138en_US
dc.relation.referencesFransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757en_US
dc.relation.referencesdoi: 10.1016/j.rdc.2009.10.001en_US
dc.relation.referencesUniversity Medical Centre Nijmegen. DAS-SCORE.NL. Home of the DAS. Available at: http://www.das-score.nl/www.das-score.nl/. Accessed 1 June 2010.en_US
dc.relation.referencesSaag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA (1997) Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463–469en_US
dc.relation.referencesdoi: 10.1136/ard.56.8.463en_US
dc.relation.referencesMasdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H (2000) Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 39:1202–1205en_US
dc.relation.referencesdoi: 10.1093/rheumatology/39.11.1202en_US
dc.relation.referencesForslind K, Ahlmén M, Eberhardt K, Hafström I, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095en_US
dc.relation.referencesdoi: 10.1136/ard.2003.014233en_US
dc.relation.referencesMöttönen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P (1998) Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with “sawtooth” strategy. Ann Rheum Dis 57:533–539en_US
dc.relation.referencesdoi: 10.1136/ard.57.9.533en_US
dc.relation.referencesRichi P, Balsa A, Muñoz-Fernández S et al (2002) Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis. Ann Rheum Dis 61:270–272en_US
dc.relation.referencesdoi: 10.1136/ard.61.3.270en_US
dc.relation.referencesYoung A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907–927en_US
dc.relation.referencesdoi: 10.1016/j.berh.2007.05.007en_US
dc.relation.referencesSaag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784en_US
dc.relation.referencesdoi: 10.1002/art.23721en_US
dc.relation.referencesLillegraven S, Kvien TK (2007) Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:827–840en_US
dc.relation.referencesdoi: 10.1016/j.berh.2007.05.004en_US
dc.relation.referencesvan der Heijde D, Klareskog L, Boers M et al (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64:1582–1587en_US
dc.relation.referencesdoi: 10.1136/ard.2004.034371en_US
dc.relation.referencesWeinblatt ME, Coblyn JS, Fox DA et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822en_US
dc.relation.referencesdoi: 10.1056/NEJM198503283121303en_US
dc.relation.referencesWeinblatt ME, Kaplan H, Germain BF et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1498en_US
dc.relation.referencesdoi: 10.1002/art.1780371013en_US
dc.relation.referencesPincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:S179–S185en_US
dc.relation.referencesMikuls TR, O’Dell JR (2000) The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 43:464–465en_US
dc.relation.referencesdoi: 10.1002/1529-0131(200002)43:2%3C464::AID-ANR30%3E3.0.CO;2-Uen_US
dc.relation.referencesFelson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33:1449–1461en_US
dc.relation.referencesdoi: 10.1002/art.1780331001en_US
dc.relation.referencesBoers M, Verhoeven AC, Markusse HM et al (1997) Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318en_US
dc.relation.referencesdoi: 10.1016/S0140-6736(97)01300-7en_US
dc.relation.referencesLandewe RB, Boers M, Verhoeven AC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347–356en_US
dc.relation.referencesdoi: 10.1002/art.10083en_US
dc.relation.referencesKlareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681en_US
dc.relation.referencesdoi: 10.1016/S0140-6736(04)15640-7en_US
dc.relation.referencesKremer JM, Genovese MC, Cannon GW et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733en_US
dc.relation.referencesUS Food and Drug Administration (FDA) Web site. FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm. Accessed 31 July 2010.en_US
dc.relation.referencesMöttönen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. The Lancet 353:1568–1573en_US
dc.relation.referencesdoi: 10.1016/S0140-6736(98)08513-4en_US
dc.relation.referencesWeinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259en_US
dc.relation.referencesdoi: 10.1056/NEJM199901283400401en_US
dc.relation.referencesKeystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411en_US
dc.relation.referencesdoi: 10.1002/art.20217en_US
dc.relation.referencesMaini RN, Breedveld FC, Kalden JR et al (2004) Sustained improvement over 2 years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065en_US
dc.relation.referencesdoi: 10.1002/art.20159en_US
dc.relation.referencesEmery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523en_US
dc.relation.referencesdoi: 10.1136/ard.2008.092932en_US
dc.relation.referencesMaini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829en_US
dc.relation.referencesdoi: 10.1002/art.22033en_US
dc.relation.referencesSmolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997en_US
dc.relation.referencesdoi: 10.1016/S0140-6736(08)60453-5en_US
dc.relation.referencesJones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96en_US
dc.relation.referencesdoi: 10.1136/ard.2008.105197en_US
dc.relation.referencesKremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865–876en_US
dc.relation.referencesKremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963en_US
dc.relation.referencesdoi: 10.1002/art.23397en_US
dc.relation.referencesCohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 54:2793–2806en_US
dc.relation.referencesdoi: 10.1002/art.22025en_US
dc.relation.referencesGenovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123en_US
dc.relation.referencesdoi: 10.1056/NEJMoa050524en_US
dc.relation.referencesKeane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44:714–720en_US
dc.relation.referencesdoi: 10.1093/rheumatology/keh567en_US
dc.relation.referencesCalabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989en_US
dc.relation.referencesdoi: 10.1136/ard.2005.043257en_US
dc.relation.referencesNathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371en_US
dc.relation.referencesdoi: 10.1111/j.1440-1746.2006.04559.xen_US
dc.relation.referencesStone JH, Holbrook JT, Marriott MA et al (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:1608–1618en_US
dc.relation.referencesdoi: 10.1002/art.21869en_US
dc.relation.referencesAskling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426en_US
dc.relation.referencesdoi: 10.1136/ard.2004.033993en_US
dc.relation.referencesGeborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703en_US
dc.relation.referencesdoi: 10.1136/ard.2004.030528en_US
dc.relation.referencesMann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602en_US
dc.relation.referencesdoi: 10.1161/01.CIR.0000124490.27666.B2en_US
dc.relation.referencesChung ES, Packer M, Lo KH, Fasanmade AA (2003) Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140en_US
dc.relation.referencesdoi: 10.1161/01.CIR.0000077913.60364.D2en_US
dc.relation.referencesRamos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biologic agents: a double-edged sword? Autoimmun Rev 9:188–193en_US
dc.relation.referencesdoi: 10.1016/j.autrev.2009.10.003en_US
dc.relation.referencesListing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412en_US
dc.relation.referencesdoi: 10.1002/art.21386en_US
dc.relation.referencesCurtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 56:1125–1133en_US
dc.relation.referencesdoi: 10.1002/art.22504en_US
dc.relation.referencesKoike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357en_US
dc.relation.referencesdoi: 10.1007/s10165-009-0197-6en_US
dc.relation.referencesSchimmel EK, Yazici Y (2009) Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol 27:446–451en_US
dc.relation.referencesHan C, Robinson DW, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol 33:2167–2172en_US
dc.relation.referencesTuresson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63:952–955en_US
dc.relation.referencesdoi: 10.1136/ard.2003.018101en_US
dc.relation.referencesSolomon DH, Karlson EW, RImm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307en_US
dc.relation.referencesdoi: 10.1161/01.CIR.0000054612.26458.B2en_US
dc.relation.referencesWolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40en_US
dc.relation.referencesPeters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331en_US
dc.relation.referencesdoi: 10.1136/ard.2009.113696en_US
dc.relation.referencesMok CC, for the working group on the use of TNF inhibitors for the treatment of rheumatic diseases in Hong Kong (2005) Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong. Hong Kong Bull Rheum Dis 5:19–25en_US
dc.relation.referencesFinckh A, Bansback N, Marra CA et al (2009) Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 151:668–669en_US
dc.relation.referencesKremer J, Fleischmann R, Halland A, et al. (2008) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study [abstract]. Ann Rheum Dis;58:abstr L14.en_US
dc.relation.referencesIsaacs JD, Olech E, Tak PP et al (2009) Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients. Ann Rheum Dis 68(Suppl 3):442en_US
dc.relation.referencesAmerican Thoracic Society, Centers for Disease Control and Prevention (2000) This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161:S221–S247en_US
dc.relation.referencesMatsue K, Kimura SI, Takanashi Y, et al. (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. [Epub ahead of print]en_US
dc.relation.referencesJi D, Cao J, Hong X, et al. (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. [Epub ahead of print]en_US
dc.relation.referencesGalloway JB, Hyrich KL, Mercer LK, et al. (2010) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). [Epub ahead of print]en_US
dc.relation.referencesDeane K (2006) Increased prevalence translates into increased fractures—Osteoporosis in RA: a common comorbidity. J Musculoskel Med 23:838–844en_US
dc.identifier.volume30en_US
dc.identifier.issue3en_US
dc.identifier.spage303en_US
dc.identifier.epage312en_US
dc.identifier.eissn1434-9949en_US
dc.identifier.isiWOS:000288216200001-
dc.description.otherSpringer Open Choice, 25 May 2012en_US
dc.identifier.citeulike8209848-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats